ORIC Pharmaceuticals, Inc.
ORIC
$5.09
-$0.22-4.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.29% | 6.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.32% | 3.27% | |||
| Operating Income | 17.32% | -3.27% | |||
| Income Before Tax | 17.31% | -5.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.31% | -5.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.31% | -5.04% | |||
| EBIT | 17.32% | -3.27% | |||
| EBITDA | 17.45% | -3.20% | |||
| EPS Basic | 17.77% | -4.88% | |||
| Normalized Basic EPS | 17.78% | -4.86% | |||
| EPS Diluted | 17.77% | -4.88% | |||
| Normalized Diluted EPS | 17.78% | -4.86% | |||
| Average Basic Shares Outstanding | 0.55% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.55% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||